# Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

> **NCT02270372** · PHASE1 · COMPLETED · sponsor: **Cascadian Therapeutics Inc.** · enrollment: 22 (actual)

## Conditions studied

- Advanced Breast Carcinoma
- Advanced Ovarian Carcinoma

## Interventions

- **BIOLOGICAL:** ONT-10, Varlilumab combination

## Key facts

- **NCT ID:** NCT02270372
- **Lead sponsor:** Cascadian Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02270372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02270372, "Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02270372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*